The Vanguard Group Discloses Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted a Form 8.3 to the Irish Takeover Panel regarding its interests in Avadel Pharmaceuticals plc. As of December 31, 2025, The Vanguard Group holds 5,864,781 US$0.01 ordinary shares in Avadel, representing 6.02% of the company's relevant securities.

Recent activities include the purchase of 5,752 shares and the sale of 5,513 shares, both transactions occurred at a unit price of 21.55 USD. No positions in cash-settled or stock-settled derivatives have been reported. Furthermore, neither indemnity arrangements nor agreements related to securities options or derivatives have been disclosed.

This filing is in compliance with Rule 8.3 of the Irish Takeover Panel Act, 1997, as updated by the Takeover Rules of 2022, which mandates transparency for entities with significant stakes in publicly-listed companies.